But PFS data are lacking, and there are questions about first and second-line plans.
ApexOnco Front Page
Recent articles
The company will start three phase 3 trials of its G12D project this year.
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
The company will be the first to take a FcRH5-targeting project into phase 3.
Like Orserdu, giredestrant works in all-comers in an ESR1m-enriched trial.
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Big pharma interest remains, but the mood is fast turning gloomy.
